Fountain Healthcare invests €5m in Inotrem

This investment expands the €39m series-B funding round raised by the company in September 2019.

In addition, Inotrem secured a €13m credit line from Kreos Capital and a €1m loan from BPI France.

Following the deal, Ena Prosser of Fountain Healthcare Partners will become a member of Inotrem's board, and Aris Contantinides of Kreos Capital will become an observer on the board.

The company intends to use the fresh financing to advance its trials in septic shock and chronic inflammatory diseases.

Previous funding
Andera and Sofinnova co-led an €18m series-A round for Inotrem in March 2014. Swiss firm Biomed Invest and Inserm Transfert Initiative also took part in the investment alongside the lead backers.

Subsequently, Morningside Ventures led a €39m series-B funding round for Inotrem in September 2019. New investor Invus and previous backers Andera Partners, Sofinnova Partners and Biomed Invest also took part in the round. Morningside's Jason Dinges joined Inotrem's board of directors.

Company
Established in 2013, Inotrem is a biotechnology company specialising in immunotherapy for acute and chronic inflammatory syndromes.

The company has developed a nangibotide formulation, LR12, which is a Trem-1 inhibitor designed to act as an amplifier of the immune response cycle and control unbalanced inflammatory responses. Inotrem is headquartered in Paris with a technology centre based in Nancy.

People
Inotrem – Jean-Jacques Garaud (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• Venture